31 August 2017
Redx Pharma Plc will present a poster on their planned first-in-human clinical trial for RXC004 at the European Society for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017, in Madrid.
|Session Date & Time||September 9, 2017, 13:15-14:15 GMT+1h|
|Session Title||Gastrointestinal Tumors, Colorectal|
|Presentation Title||Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening|
|Session Location||Hall 8|
|First author||Matilda Bingham|
Iain Ross, Chairman, commented:
We're delighted to present new scientific data on our most advanced program, the Porcupine inhibitor RXC004 as it moves closer to the clinic. We have a strong portfolio of research assets and continue to look for novel opportunities in several therapeutic classes in oncology and immunology.